Healthcare AI News — Diagnostics, Drug Discovery & More
AI in medicine, diagnostics, and drug discovery, with an eye on practical applications for healthcare businesses.
Medical AI, diagnostics, drug discovery, and clinical AI tools — including FDA approvals and the AI reshaping healthcare and biotech.
AstraZeneca and Oracle Partner on AI to Accelerate Clinical Trial Recruitment and Safety Monitoring
AstraZeneca and Oracle have announced a global AI collaboration aimed at speeding up the journey from drug discovery to patient treatment, with a specific focus on using AI to identify eligible patients faster and monitor safety signals continuously across a medicine's lifecycle. AstraZeneca CEO Pascal Soriot described the deal as bringing together 'leading players in healthcare and AI on a global scale.' The partnership adds to AstraZeneca's recent AI activity, which also includes a separate deal with Insitro for MASH and cardiomyopathy drug discovery.
Applied Clinical Trials OnlineMass General Brigham Opens FaceAge AI Tool to Public, Launches Clinical Trials for Cancer Survival Prediction
Mass General Brigham has made its FaceAge AI tool publicly accessible, allowing anyone to upload a photo to receive an estimate of their biological age. Researchers have also published a validation study and launched two clinical trials testing whether the tool can predict cancer survival and surgical outcomes. Lead researcher Dr. Hugo Aerts called it 'the first demonstration that an AI model can directly predict cancer survival from a simple photograph.'
The Boston GlobeEpic Launches 'Connectors' to Let AI Agents Access Third-Party Apps, Positioning Itself as Healthcare's AI Orchestration Layer
Epic has introduced 'Connectors,' a capability allowing its AI agents — patient assistant Emmie, clinician assistant Art, and revenue cycle AI Penny — to access data and perform tasks in third-party applications outside the EHR. Developers can now integrate their apps into Epic's Agent Factory, and healthcare organizations can connect custom-built AI through the same interface. Epic is explicitly positioning Agent Factory and its AI assistants as the orchestration layer for cross-system clinical and administrative workflows.
Fierce HealthcareAI Designs Experimental Antivenom in Drug Discovery Breakthrough, but Clinical Trial Bottleneck Remains
An investigation by Hunterbreak details how AI — including Anthropic's Claude operating with fewer restrictions — has been used to design experimental antivenom compounds, compressing the molecular design phase that once took years. However, experts including former FDA leader Dr. Amy Abernethy warn that the bottleneck has simply shifted: AI can generate candidate molecules quickly, but clinical trials still take years and the path to FDA approval remains unchanged. The story illustrates both the genuine acceleration AI brings to drug discovery and its hard limits.
HunterbreakFDA Struggles to Keep Pace as Health AI Moves from Admin Tools to Autonomous Clinical Agents
A detailed analysis in JD Supra's FDA in Flux newsletter documents how clinical AI has rapidly evolved from simple administrative assistants to agentic systems with meaningful clinical autonomy, outpacing the FDA's regulatory frameworks. The American Medical Association has called for new governance processes, while the FDA acknowledges it is in reactive mode. Stakeholders are being warned to build their own internal governance rather than waiting for federal rules.
JDSupraMHRA Deepens FDA Collaboration on AI Medical Devices, Moves from Policy to Practice with 'AI Airlock' Initiative
The UK's Medicines and Healthcare products Regulatory Agency (MHRA) is presenting its next phase of AI medtech regulation at the AdvaMed MedTech Conference, highlighting its 'AI Airlock' sandbox program and plans for closer alignment with the US FDA. Deputy Director Jessica Paulsen described the approach as lifecycle-based and proportionate, emphasizing that global AI technologies require international regulatory coordination. The move signals a shift from guidance documents to active regulatory testing of AI medical products.
SelectScienceMasimo's SmartSET Gets FDA Clearance for AFib Detection in Pulse Oximetry Workflow
Masimo, a Danaher company, has received FDA 510(k) clearance for AFib detection capability on its Radius VSM wearable through the smartSET platform, which uses AI-driven pattern recognition to identify subtle physiological shifts between routine clinical rounds. Combined with its previously cleared AI-enabled opioid-induced respiratory depression (OIRD) detection, smartSET expands pulse oximetry beyond individual readings into continuous AI-monitored surveillance. The system targets the dangerous gaps in patient monitoring that occur between nurse checks on general care floors.
BioSpaceGE HealthCare's AI Radiation Contouring Tool and Medtronic's Smart Insulin Pump Highlight Real-World Medical AI Deployments
A GeneOnline analysis of six leading medical AI advances as of October 2026 highlights two systems already in clinical use: Medtronic's MiniMed 780G, which makes 288 automated insulin dosing decisions per day without user input, and GE HealthCare's MIM Contour ProtégéAI+ 2.0, which automates the labor-intensive tumor and organ outlining step in radiation therapy planning. Both tools succeeded by automating a narrow, measurable task within workflows clinicians already use. The analysis notes that AI tools performing focused, verifiable tasks move fastest through regulatory and clinical adoption.
GeneOnlineAstraZeneca and Insitro Partner on AI-Driven Drug Discovery for MASH and Cardiomyopathy, Worth Up to $1.5B
AstraZeneca has signed a drug discovery collaboration with AI biotech company insitro, applying artificial intelligence to target identification and therapeutic design in metabolic dysfunction-associated steatohepatitis (MASH) and cardiomyopathies. Insitro will receive $40 million upfront and is eligible for up to approximately $1.46 billion in development and commercial milestones, plus royalties. The deal remains at the discovery stage, with no named drug candidates yet.
Pharmaceutical ExecutiveGallup Survey: 14 Million US Adults Skipped Doctor Visits After Using AI for Health Advice
A Newsweek report citing a Gallup survey of over 5,500 US adults found that roughly 14 million Americans reported skipping a healthcare provider visit after consulting AI for health questions. Medical professionals warn that AI-generated health advice harms are often hidden from clinicians and regulators, and researchers are calling on social media platforms and search engines to improve labeling and use medically vetted information in AI summaries.
NewsweekJAMA Study Finds Clinicians Across All Specialties Increasingly Using AI for Treatment Decisions, Often Outside Their Own Field
New research published in JAMA reveals that clinicians are routinely using AI tools to guide treatment and medication decisions — and frequently querying AI about conditions outside their own specialty. Harvard Medical School researchers noted this pattern diverges sharply from the diagnostic tasks that current AI evaluations focus on, suggesting the real-world use case for clinical AI is broader and more consultative than assumed. The findings are prompting policymakers and professional societies to reconsider how AI integration guidelines are developed.
Cardiovascular BusinessNeoGenomics Expands AI Digital Pathology Infrastructure Partnership With Indica Labs
Cancer diagnostics company NeoGenomics has deepened its partnership with Indica Labs to scale AI-driven digital pathology across its clinical enterprise, aiming to give pathologists and providers faster and more consistent access to diagnostic insights. The Indica Labs HALO AP platform holds CE-IVDR marking for diagnostic use in Europe and the UK, though it remains research-only in the US. The collaboration is designed to accelerate NeoGenomics' ability to bring new AI diagnostic innovations into clinical practice and support future clinical trial partnerships.
Clinical Lab ProductsLabcorp Acquires Diagnostics Company with FDA-Approved AI-Adjacent Prostate Cancer Blood Test for $872 Million
Labcorp has agreed to acquire a medical diagnostics company for up to $872 million, gaining ownership of the 4Kscore Test — an FDA-approved blood analysis that predicts aggressive prostate cancer risk before a biopsy is performed. The deal expands Labcorp's clinical, women's health, urology, and corrections testing capabilities nationwide. The acquisition signals continued consolidation in diagnostics as AI-adjacent precision testing tools become strategic assets.
HealthExecSEERS AI Arrhythmia Screening Gets Abu Dhabi Ethics Approval, Eyes UAE National Health Program
Korean wearable diagnostics company SEERS has received Institutional Review Board approval in Abu Dhabi to pilot its AI-based arrhythmia screening service with SEHA Clinics, the UAE's largest public healthcare network. This ethics approval is described as the final step before potential inclusion in the UAE's national health screening program. The company's mobiCARE wearable already holds both FDA clearance and Health Canada approval.
Korea Biomedical ReviewUtah Approves First US Program Allowing AI to Issue New Prescriptions Without Doctor Oversight
Utah has approved a first-of-its-kind program allowing an AI system to autonomously diagnose patients and issue initial prescriptions — going beyond the existing 'long-term medication renewal' use case seen elsewhere. The program currently focuses on acne treatment, where AI evaluates skin condition severity and issues prescriptions if a score threshold is met, automatically transferring complex cases to a human physician. The move marks a significant regulatory milestone and raises broader questions about the appropriate scope of autonomous AI decision-making in clinical settings.
36 KrARPA-H Awards $62.7 Million to Develop First FDA-Authorized Agentic AI System for Cardiovascular Care
Duke University researchers have received up to $15.5 million as part of a $62.7 million ARPA-H program called ADVOCATE, which aims to create the first FDA-authorized agentic AI system for cardiovascular care. Three health-tech companies will build the AI agents, which will be tested across five health systems and rural sites, while Stanford will develop a supervisory safety layer. Duke's SYMPHONY consortium will handle systematic evaluation and monitoring of the deployed tools at scale.
The Duke ChronicleAI Biotech Iambic Therapeutics Raises $150 Million in Nasdaq IPO to Fund Oncology Pipeline
Iambic Therapeutics, an AI-driven drug discovery company focused on oncology, priced its IPO at $150 million and began trading on Nasdaq under the ticker 'IAM.' The company, co-founded by a Caltech professor and an AI researcher from the University of Bristol, uses AI to accelerate small-molecule drug discovery. Iambic has now raised over $400 million in total since its 2021 Series A, reflecting sustained investor confidence in AI-native biotech.
Fierce BiotechSuki Raises $90 Million Series E to Build AI 'Intelligent Operating System' for Clinical Workflows
Suki, maker of an AI voice documentation tool widely used by clinicians, secured $90 million in Series E financing, bringing total funding to over $258 million. CEO Punit Soni described the goal as building an 'intelligent operating system that understands the patient,' going well beyond transcription to full clinical workflow integration. The funding follows expanded partnerships with Rush University System for Health and Zoom's Workplace for Clinicians platform.
MobiHealthNewsAstraZeneca Signs $1.5 Billion Deal with insitro for AI-Powered Drug Target Discovery
AstraZeneca is paying insitro $40 million upfront, with up to $1.46 billion in additional milestones, to use insitro's AI platform to identify novel drug targets for liver and cardiovascular diseases. The platform combines human cellular data with AI-enabled target identification to pinpoint causal disease biology, aiming to accelerate programs that might otherwise stall in early discovery. The deal is part of AstraZeneca's broader AI push, which also includes acquisitions and licensing agreements with Modella AI and Owkin.
Fierce BiotechPharma Sector Doubles Down on AI Partnerships to Halve Drug Development Timelines and Costs
Reuters reports that pharmaceutical companies are significantly expanding AI investments across their R&D pipelines, with industry forecasts suggesting machine learning could halve early-stage development timelines and costs within three to five years by optimizing target discovery, molecule design, and clinical trial planning. The article catalogs major AI partnerships struck between 2025 and September 2026, including a newly announced Zealand-Generate partnership, reflecting a wave of deal-making as pharma firms race to automate laboratories and apply predictive modeling throughout their pipelines. The trend is moving from experimental pilots to core pipeline strategy at major drug companies.
ReutersGlobal AI in Healthcare Reaches 1,600+ FDA-Authorized Devices as Imaging and Drug Discovery Lead Adoption
A comprehensive 2026 overview of global AI in healthcare notes that the FDA has now authorized more than 1,600 AI-enabled medical devices as of September, with radiology accounting for 76% of cleared tools — algorithms are now routinely flagging lung nodules, strokes, and breast abnormalities within seconds. Beyond imaging, AI is shortening early drug discovery by screening molecules, predicting protein interactions, and identifying trial sites and eligible patients faster. The FDA's 2025 draft guidance on predetermined change control plans now allows manufacturers to update AI models without a new submission for every change, streamlining the path to market.
Global Risk CommunityIGC Pharma Unveils PRISM AI Platform Targeting Alzheimer's Risk Assessment in Clinical Workflows
Clinical-stage biotech IGC Pharma introduced PRISM, an AI platform designed to move Alzheimer's risk assessment from prediction toward actionable clinical decisions, complementing its existing MINT-AD tool. The company is evaluating commercialization pathways including licensing PRISM to physician practices, memory clinics, pharmaceutical companies, clinical trial sponsors, and insurers. IGC's AI portfolio sits alongside its Phase 2 CALMA clinical trial for its lead drug candidate IGC-AD1.
StockTitanAgilent Acquires AI Digital Pathology Company Proscia for Up to $270 Million
Agilent Technologies announced it will acquire Proscia, an AI-powered digital pathology platform trusted by 16 of the top 20 pharmaceutical companies and named 2026 Best in KLAS for Digital Pathology in both US and European markets, for up to $270 million. Proscia's Concentriq platform holds FDA 510(k) clearance for primary diagnosis and will be integrated with Agilent's existing companion diagnostics and laboratory technology business. The deal is designed to combine pathology data generation with AI-powered analysis to accelerate biomarker research and drug discovery.
BioSpaceFDA Clears AIRS Medical's SwiftSight-BodyComposition AI MRI Tool via 510(k) Pathway, But Screening Benefit Remains Unproven
The FDA has granted 510(k) clearance to AIRS Medical's SwiftSight-BodyComposition AI tool for MRI analysis, confirming substantial equivalence to a prior legally marketed device. The clearance does not constitute proof of clinical benefit, as the 510(k) pathway does not require clinical outcomes data for most submissions. Analysts note the distinction is important as AI-powered imaging tools accumulate regulatory approvals without equivalent evidence of improved patient outcomes.
StreamlineNatera Earns FDA Breakthrough Device Designation Across 12 Cancer Types for Its Liquid Biopsy Test
Natera has received FDA Breakthrough Device designation for its liquid biopsy cancer detection test, with the designation covering 12 cancer types. The Breakthrough Device pathway is designed to accelerate development and review of medical devices that provide more effective treatment or diagnosis of life-threatening conditions. Natera stock was trading at EUR 360.20 on October 12, reflecting positive market response to the designation.
Ad-hoc NewsGoogle Publishes Comprehensive Overview of AI Applications Across Drug Discovery, Cancer Detection, Genetic Diagnosis, and Disease Outbreak Forecasting
Google has released a detailed public-facing summary of how its AI tools — including AlphaFold — are accelerating medical research across multiple domains. Highlights include AlphaFold being used by Barcelona researchers to screen 30,000 compounds for Chagas disease treatment, leading to identification of two repurposable FDA-approved drugs. Google also describes geospatial AI tools for outbreak prediction and machine learning systems supporting cancer detection and administrative task reduction for clinicians.
Google BlogUK Accepts All 44 Recommendations from AI Healthcare Commission, Shifts to Lifecycle Regulatory Model
The UK government has accepted all 44 recommendations from its clinician-led National Commission into the Regulation of AI in Healthcare, committing to a continuous, lifecycle-based regulatory framework for medical AI rather than one-time static approvals. The MHRA's International Reliance framework is also rolling out, enabling faster domestic clearance by recognizing approvals from the US FDA and Australia's TGA. The moves give UK health AI companies a potential competitive edge in global markets.
Healthcare DigitalAI Clinical Prediction Models in Drug Trials Heading Toward Regulatory Crisis Within 18 Months
A new analysis warns that AI-driven clinical prediction models embedded in drug trials are operating with far less transparency than AI medical devices, creating a looming regulatory gap. Post-market outcomes data for drugs approved on AI-stratified trial populations will start producing unexplainable signals within 12-18 months, forcing a confrontation between FDA's device AI guidance and the absence of equivalent rules for drug trials. Three stroke dataset retractions in 2026 involving models already in clinical use have previewed the problem at smaller scale.
Clinical Trial VanguardAI Drug Discovery Has Received $60B in Funding But Produced Zero FDA-Approved End-to-End AI Medicines
A new analysis applying the Dalio bubble framework to AI healthcare investment finds that despite approximately $60 billion deployed across roughly 175 clinical-stage AI drug discovery programs since 2019, no FDA-approved medicine has been produced where discovery and optimization were fully AI-derived end-to-end. Separately, over 1,000 AI medical algorithms have received FDA clearance, but commercial deployment is stalled by a systemic reimbursement gap — particularly in radiology, which accounts for 78% of cleared algorithms.
Healthcare DigitalQIAGEN Launches AI-Powered Discovery Platform to Accelerate Drug Target Identification
QIAGEN has introduced the QIAGEN Discovery Platform, which integrates AI with the company's biomedical knowledge base and molecular datasets to support pharmaceutical drug discovery. The platform is designed to help researchers identify drug targets and biomarkers, generate hypotheses, and automate portions of the discovery pipeline. The launch comes alongside expanded AI-powered bioinformatics tools targeting academic and pharmaceutical R&D customers across its 500,000-customer base.
StockTitan / QIAGENAI and Biology Converge: AlphaGenome Atlas, GPT-Rosalind, and Anthropic Life Sciences Signal New Era
A CEPA analysis highlights a cluster of major AI-biology announcements from September 2026: Google DeepMind released AlphaGenome Atlas with predictions for nine billion possible single-letter human genome changes, Anthropic launched a dedicated life-sciences research group after Claude identified novel enzymes, and OpenAI introduced GPT-Rosalind as a specialized biology model. Together, these moves signal that frontier AI labs are making serious institutional bets on biological research as a primary application domain. The convergence is already accelerating cancer immunotherapy research by automating neoantigen identification.
CEPADonut Robotics Partners with Japanese Nursing Home Operator Charm Care to Develop Eldercare Humanoids
Donut Robotics has entered a capital and business alliance with Charm Care Corporation, one of Japan's major nursing home operators, to develop humanoid robots specifically for eldercare applications. The deal directly connects humanoid robot development to an operational end-user with real deployment environments and patient care requirements. It follows Japan's national AI strategy positioning AI as a demographic technology to address its aging population crisis.
Robotics & Automation NewsRoche Acquires PathAI for $750M, Accelerating AI Diagnostics in Digital Pathology
Roche has acquired PathAI in a $750 million deal, signaling a major consolidation move in the rapidly growing digital pathology market. PathAI's AI-powered diagnostic tools for analyzing whole-slide pathology images will be integrated into Roche's broader diagnostics and oncology portfolio. The acquisition reflects growing confidence that AI pathology tools are mature enough for large-scale clinical deployment.
OpenPR / DataM IntelligenceUtah Becomes First State to Allow AI to Prescribe Medication Without Direct Doctor Oversight
Utah startup Nolla Health has become the first company in the U.S. authorized to issue AI-generated prescriptions without direct human physician oversight, starting with acne medications. The first 100 patient prescriptions will be reviewed by a physician, but the goal is to fully automate routine care decisions for common conditions and eventually expand to an AI-powered personal doctor platform. A separate but related approval was also granted to August AI for AI-assisted prescription renewals for chronic illness patients, where a physician still reviews each renewal at $4 per transaction.
Los Angeles TimesSpringer Nature Retracts AI Research Paper After Discovering Undisclosed Use of Generative AI and Fabricated Citations
Springer Nature's journal Discover Artificial Intelligence has formally retracted a 2024 review article after concluding that generative AI was used to write portions of the manuscript without disclosure, and that multiple citations appeared contextually incorrect — a pattern consistent with AI hallucination. The retracted paper was a critical review of AI applications in communication research, a genre that depends on accurate literature synthesis. The case adds to a growing list of academic retractions linked to undisclosed AI authorship.
Bioengineer.orgHello Robot Receives $3M NIH Grant to Adapt Stretch Robot for Elder Care and Alzheimer's Support
Hello Robot has been awarded a Phase IIB Small Business Innovation Research grant from the National Institute on Aging to advance its Stretch mobile manipulator robot for supporting older adults with mild cognitive impairment and early Alzheimer's dementia, in partnership with the University of Illinois Urbana-Champaign. The project will explore Stretch's use for cognitive assistance, social engagement, and safety management across both home and care facility settings. The grant will fund commercialization efforts to ready Stretch for real-world elder care deployment.
Robotics & Automation NewsFDA Plans to Highlight Aging and Longevity Medicine in Upcoming Regulatory Framework Update
FDA Chief Scientist Steven Kozlowski signaled at a Harvard aging research conference that the agency plans to update its Favorable Aging and Rejuvenation Standards (FARS) framework to more formally address aging and longevity medicine as a regulatory category. The move reflects growing scientific consensus that aging is a shared risk factor across many chronic diseases and that biomarkers of biological aging could be used in clinical trial design. The update would help clarify how AI-designed anti-aging drugs and longevity interventions seek regulatory approval.
Genetic Engineering & Biotechnology NewsGE HealthCare Appoints New Global Chief AI Officer as It Holds More FDA-Cleared AI Medical Devices Than Any Other Company
GE HealthCare has named Rodolphe Katra, formerly Chief AI Officer at Medtronic, as its new Global Chief AI Officer, with a mandate to connect AI across the company's devices, software, and healthcare data platforms. The appointment comes as GE HealthCare reports 134 FDA-authorized AI-enabled medical devices — more than any other medtech company. Katra will report to the company's Global Chief Science and Technology Officer.
Healthcare DigitalAI 'Mind-Reading' Tool Reconstructs Visual Images Directly From Brain Scans
Researchers at the Weizmann Institute of Science have developed an AI system that can reconstruct images of what a person is seeing by analyzing their brain scans, in what is being described as a significant step toward brain-computer interfaces. The system works by mapping neural activity patterns to visual representations, opening potential applications in communication for paralyzed patients and in understanding perception disorders. While still early-stage, the research marks a notable advance in the intersection of neuroscience and generative AI.
NewsmaxNHS England Pilots Rapid AI Genomic Test That Delivers Brain Tumor Diagnoses in Days
NHS England has announced a major pilot of a rapid genomic test capable of delivering definitive brain tumor diagnoses in days rather than the weeks typically required by conventional methods. The test uses AI-assisted genomic analysis to accelerate diagnosis, which is critical for treatment planning in fast-moving cancers. If successful at scale, the pilot could significantly reduce the time-to-treatment gap that affects outcomes for brain tumor patients across the UK.
RSM Real Economy